The long-debated question of whether mineralocorticoid receptor antagonists are effective for heart failure with mildly reduced or preserved ejection fraction has been answered in a new trial.
, a third-generation nonsteroidal MRA, reduced the primary endpoint of worsening heart failure events and death from cardiovascular causes by 16% compared with placebo ; no significant effect was seen on cardiovascular death .
The results for the primary outcome were consistent across all prespecified subgroups, including those defined according to baseline left ventricular ejection fraction and baseline use of SGLT2 inhibitors.with MRAs, and potassium levels greater than 6.0 mmol/L were more common in the finerenone than in the placebo group . However, there were few hospitalizations because of hyperkalemia in the finerenone or placebo groups , and no episodes of hyperkalemia led to death.
The magnitude of benefit was similar to that seen in trials of SGLT2 inhibitors in similar populations, McDonagh reported. As in those trials, there was no reduction in cardiovascular mortality most likely because of the lack of power in this relatively low-risk group., did not show a clear benefit in patients with heart failure and preserved ejection fraction, but that trial was found to have flaws in the Russian and Eastern European cohorts.
"Many of us suspected that MRAs were effective in heart failure with preserved ejection fraction after TOPCAT, but we didn't have definitive data to prove it. Now we finally have proof that MRAs are effective in this population," said Christopher Kramer, MD, chief of cardiology at the University of Virginia in Charlottesville.
"While subgroup analyses in FINEARTS-HF suggest benefits in both these situations, more data are needed, which will hopefully come from further trials," he said.The FINEARTS-HF trial gives validation to the TOPCAT North American data, and indicates that the benefit is probably a class effect, said Kramer.
Cardiovascular Imaging Cardiac Imaging CV Imaging Heart Ejection Fraction EF - Ejection Fraction Left Ventricular Ejection Fraction LVEF Hypertension Hyperkalemia Hyperkalaemia Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Europe European Hypokalemia Antihypertensive
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Topline Finerenone Results Point to Advance in Heart FailureTopline numbers show a significant reduction in major events in preserved heart failure, and now final results from the FINEARTS-HF trial are eagerly awaited.
Read more »
Weight loss drug's heart benefits extend to people with heart failureThe researchers looked at data from 4,286 people -- out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial who were randomly assigned either semaglutide or a placebo -- who were followed up over an average of more than three years.
Read more »
Wegovy Helps Patients With Heart Failure Avoid Heart Attack, StrokeResearch has already proven that the blockbuster weight-loss drug Wegovy (semaglutide) can slash a person's odds for heart attacks and strokes, and now more data from the same trial suggests that's even true for very ill patients with heart failure.
Read more »
Breakthrough heart MRI technique accurately predicts heart failure risk in general populationMRI scans could replace invasive heart tests, as new research shows they can reliably estimate pressures inside the heart to predict if a patient will develop heart failure.
Read more »
Dialysis Benefits in Chronic Kidney Failure Come With Trade-OffsSurvival may be longer among older people with chronic kidney failure, but those patients commonly have less time at home compared with those choosing medical management.
Read more »
Benefits Data Trust’s closure should prompt us to rebuild the flawed public benefits systemWhen BDT answered its last call in Philadelphia last week, the city lost an important player in the effort to make public benefits accessible. But it shouldn't have had to exist in the first place.
Read more »